Why the study?
Major guidelines recommend NOACs over warfarin for AF, but prescription behaviors needed evaluation to see how they align with clinical evidence.
What factors influence the selection of specific NOACs for stroke prevention in patients with non-valvular atrial fibrillation aged ≥65 years?
What factors influence the selection of specific NOACs for stroke prevention in patients with non-valvular atrial fibrillation aged ≥65 years?
Answers are grounded in this paper and cite their sources.
Real-world prescription patterns of NOACs in older NVAF patients show rivaroxaban is most commonly used, with apixaban preferred in older, female, and renal disease patients, aligning with known safety profiles.
BACKGROUND: Major atrial fibrillation (AF) guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over warfarin, except in rare clinical circumstances based on 4 randomized controlled trials comparing each NOAC with warfarin. We aimed to investigate the current NOAC prescription behaviors in alignment with the recent clinical evidence available. METHOD: We conducted a cross-sectional analysis of NOAC-using patients with non-valvular atrial fibrillation (NVAF) who were aged ≥65 years on the index date (July 1, 2018) based on nationwide claims data. The types of NOACs being taken were analyzed using chi-squared tests, and factors influencing NOAC selection were identified using multinomial logistic regression analysis. RESULTS: A total of 6,061 patients were included. Among the 4 NOACs, rivaroxaban was the most used NOAC. Patients aged ≥75 years (odds ratio [OR] = 1.270, confidence interval [CI] = 1.089-1.450) and women (OR = 1.148, CI = 1.011-1.284) were more likely to use apixaban relative to rivaroxaban. Patients with prior stroke/transient ischemic attack/thromboembolism had higher odds of using dabigatran (OR = 1.508, CI = 1.312-1.704) and apixaban (OR = 1.186, CI = 1.026-1.346). Patients with renal disease had higher odds of using apixaban (OR = 1.466, 95% CI = 1.238-1.693). These findings are consistent with the efficacy and safety profiles reported in pivotal trials and observational studies comparing individual NOACs. CONCLUSION: Among the 4 NOACs, rivaroxaban was the most commonly used NOAC. Apixaban was preferred for patients aged ≥75 years, females, and patients with renal disease.
No takes yet. Share an insight, caveat, or question.
Park et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: